Genprex, Inc. · NASDAQ:GNPX
Genprex — Investor Presentation (February 2020)
23 slides from Genprex's investor presentation, Feb 5, 2020
Slide 1: Reprogramming the Course of Cancer
©) Genprex REPROGRAMMING THE COURSE OF CANCER NASDAQ: GNPX
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS Statements containedin this presentation regarding matters that are not historical facts are “forward-lookingstatements” within the meaning ofthe Private Securities Litigation Reform Act of 1995. Because such statements are subjectto risks and uncertainties, actual results
Slide 3: 21st Century Gene Therapy for Cancer
21ST CENTURY GENE THERAPY FOR CANCER LEARNING FROM THE PAST TO TREAT PATIENTS IN THE PRESENT, WITH TECHNOLOGY EQUIPPED TO CHANGE THE FUTURE WHO WE ARE Genprex, Inc. isa clinical-stage gene therapy company developing anew approach to treating cancer based upon a novel proprietary technology platform,
Slide 4: Company Highlights
COMPANY HIGHLIGHTS KEY CORPORATE ACHIEVEMENTS Genprexis developing potentially life-changing gene technologies based upon our novel proprietary technology platform, including our initial product candidate, Oncoprex™ immunogene therapy. Phase | clinical trial showed that Clinical and pre-inical data
Slide 5: Genprex received Fast Track Designation
ON Genprex received Fast Track Designation for Oncoprex + EGFR inhibitor osimertinib for NSCLC patients that progressed on osimertinib alone imertinib (Astrazeneca’s Tagrisso®) is n pace for $3B+ 1.2019 worldwide Haross sales, and itis their highest igrOssing product FTO is for therapies showing pot
Slide 6: Problem: Few Patients Benefit from Modern Therapies
PROBLEM: FEW PATIENTS BENEFIT FROM MODERN THERAPIES LIMITATIONS TO NSCLC TREATMENT TARGETED THERAPIES IMMUNOTHERAPIES PATIENT ELIGIBILITY OF patients havean activating OF patients are eligible for EGER mutation and can benefit ‘and benefit from from targeted therapies! immunotherapies? “Few patients
Slide 7: Solution: Novel Platform to Treat Cancer
SOLUTION: NOVEL PLATFORM TO TREAT CANCER GENES Multiple tumor SYNERGIES . suppressor genes Modern approach using combination therapy CANCERS Genetic mutations found in other cancers Genprex Nasdaq: GNPX
Slide 8: Oncoprex Targets Cancer at Its Core
ONCOPREX™ TARGETS CANCER AT ITS CORE DOTAP: CHOL-TUSC2 ! y\ aX | pi 2 CONTROLS CELL SIGNALING STIMULATES APOPTOTIC PATHWAYS = MODULATES IMMUNE RESPONSE Pan-kinase inhibition decreases cell Leads to programmed cell death Promotes immune activity against proliferation cancer Nasdaq: GNPX
Slide 9: Oncoprex Inhibits Key Cell Signaling
ONCOPREX INHIBITS KEY CELL SIGNALING TUSC2 TUMOR SUPPRESSOR GENE HAS PAN-KINASE ACTIVITY THAT CAN OVERCOME CANCER RESISTANCE PATHWAYS Cell Survival Proliferation Nasdaq: GNPX
Slide 10: Oncoprex Affects Tumor Immunogenicity
ONCOPREX AFFECTS TUMOR IMMUNOGENICITY TUSC2 ALSO SHOWN TO UPREGULATE NK AND CD8+ T CELLS, AND DOWNREGULATE PD-L1 RECEPTORS ILas mRNA wee 28. ig Re ve Ribosome IL-5 ? Immature NK cells NK cells Nasdaq: GNPX
Slide 11: Nanovesicle Delivery System
NANOVESICLE DELIVERY SYSTEM CATIONIC LIPID NANOVESICLE CARRIES DRUG TO TUMORS Positively charged rnanovesile Tusczgene iS) ° Oo} o® —> — e 1S) Negatively charged cancer cell Nanovesicle attaches to Cancer'killing genes Cell death cancer cell ike a magnet integrate into cell Our non-viral, biodegrada
Slide 12: Research and Development Pipeline
RESEARCH AND DEVELOPMENT PIPELINE PATHWAY TO APPROVAL PRECLINICAL ccunicaL ‘cUNICAL ‘cUNIcaL PHASE PHASE? PHASES CONCOPREX + TARGETED THERAPIES: [ONCOPREX + MMUNOTHERAPIES = I us reanamscoeieatin © Genprex Nasdaq: GNPX
Slide 13: Oncoprex Dose Escalation Study
ONCOPREX DOSE ESCALATION STUDY Explore toxicity and tolerability in patients. Phase | monotherapy results: 31 Stage IV patients with at least 1 of 6 trial doses 23 patients evaluable Cancer growth halted in 5 of 23 patients Stable disease n=5; responses n=3 Maximum Tolerated Dose (MTD) established W
Slide 14: Oncoprex + Erlotinib Combination
ONCOPREX + ERLOTINIB COMBINATION PHASEIl PRELIMINARY DATA IN SUBJECTS WITH OR WITHOUT EGFR MUTATIONS = B LINE OF RIOR 2APY PATIENT EGFR STATUS RESPONSE PRIOR THERAPY Taree Positive (exon 18420) cR chemo 3 Negative 2496 regression Target Lesion Chemo /ant-PD1 2 3096 regression one Target Lesion ° Neg
Slide 15: Oncoprex + Erlotinib Combination Swimmer Plot
EGFR status/mutation ONCOPREX + ERLOTINIB COMBINATION ‘Swimmer Plot of Best Response, with Time on Study Negative + Negative 4 Positive (exon 18+20) 4 Negative 4 Negative 4 Negative 4 Negative + Negative 4 Positive (exon 21) 4 Negative 4 Negative 4 Positive (exon 21) + sD + Chemotherapy ‘4 Chemother
Slide 16: Oncoprex Shows Synergy with Immunotherapies
ONCOPREX SHOWS SYNERGY WITH IMMUNOTHERAPIES TUSC2 IS SYNERGISTIC WITH ANTI-PD1 IN A SYNGENEIC MOUSE MODEL OF LUNG CANCER ‘Survival on Lung Metastasis Model Non-Treated ‘Tusc?-treated z = tsee 5 = tuscaspo: ge = Tuscarporscriaa é of 10 16 20 26 Days TUSC2+anti-PD1 combination significantly prolonged
Slide 17: Oncoprex Shows Synergy with Immunotherapies
ONCOPREX SHOWS SYNERGY WITH IMMUNOTHERAPIES TUSC2 IS SYNERGISTIC WITH ANTI-PD1 IN A HUMANIZED MOUSE MODEL OF LUNG CANCER TUSC2 + PEMBRO TUSC2 + PEMBRO + CHEMO. Strong antitumor immune responses of anti-PD1 TUSC2+anti-PD1+chemo combination resulted were found against PDX tumors developed in in metast
Slide 18: Timeline
TIMELINE HIGHLIGHTS FROM OUR JOURNEY 2009 Genprexwas founded 2012 Phase! monotherapy 2015 Commenced initial preclinical 2018 Initiated adaitional pre- linica trial of Oncoprex studies evaluating Oncoprex ‘inked research with is published incombinationwith MDAC for Oncoprex~ immunotherapies Immunothe
Slide 19: Key Milestones 2020
KEY MILESTONES 2020 MANUFACTURING CLINICAL + Complete preparation of lipid nanoparticle ind file INDs for Oncoprex + delivery system and TUSC2 DNA plasmid osimertinib and Oncoprex + for clinical expansion pembrol + Complete manufacturing scale-up to. Contract with new clinical: begin enrolling patie
Slide 20: Meet Our Team
MEET OUR TEAM COMPANY MANAGEMENT RODNEY VARNER, JD Chairman & CEO + 30+ years of expertise in corporate law, including corporate governance, in biotech industry + Former owner of securities broker dealer firm RYAN CONFER, MS. CFO + 10+ years of C-Level experience in emerging technology companies + E
Slide 21: Scientific Advisory Board
MEET OUR TEAM SCIENTIFIC ADVISORY BOARD JACK A. ROTH MD, FACS, Chairman + Professor and Bud Johnson Distinguished Clinical Chair, Department of Thoracicand Cardiovascular Surgery; Chief, Section of Thoracic Molecular Oncology; Professor of Molecularand Cellular Oncology; UT MD Anderson Cancer Center
Slide 22: Board of Directors
MEET OUR TEAM BOARD OF DIRECTORS RODNEY VARNER, JD ROBERT PEARSON, MBA Chairman of the Board Board Director 30+ years of expertisein corporate law, including + Strategic Advisor, W20 Group corporate governance, n biotech industry + Deep global media and communications experience + Former owner of se
Slide 23: Genprex
oO Genprex NASDAQ: GNPX 1601 Trinity St, Bldg B, Suite 3.322, Austin TX 78712 | 1 Broadway, Cambridge, MA02142 (877)774-GNPX | investors@genprex.com Nasdaq: GNPX